Anti-CTGF Antibody Picoband®

Western blot analysis of CTGF using anti-CTGF antibody (PB9541).
Electrophoresis was performed on a 5-20% SDS-PAGE gel at 70V (Stacking gel) / 90V (Resolving gel) for 2-3 hours.
Lane 1: Rat Liver Tissue Lysate at 50ug,
Lane 2: Rat Thymus Tissue Lysate at 50ug,
Lane 3: HELA Whole Cell Lysate at 40ug.
After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-CTGF antigen affinity purified polyclonal antibody (Catalog # PB9541) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for CTGF at approximately 38 kDa. The expected band size for CTGF is at 38 kDa.

IHC analysis of CTGF using anti-CTGF antibody (PB9541).
CTGF was detected in a paraffin-embedded section of human mammary cancer tissue. Heat mediated antigen retrieval was performed in EDTA buffer (pH 8.0, epitope retrieval solution). The tissue section was blocked with 10% goat serum. The tissue section was then incubated with 1 μg/ml rabbit anti-CTGF Antibody (PB9541) overnight at 4°C. Biotinylated goat anti-rabbit IgG was used as secondary antibody and incubated for 30 minutes at 37°C. The tissue section was developed using Strepavidin-Biotin-Complex (SABC) (Catalog # SA1022) with DAB as the chromogen.

The key fibrosis-related gene and signaling pathway that are inhibited by KD (A) The results of high-throughput sequencing of the transcriptome showed that the expression of CTGF gene increased after irradiation (B) The results of high-throughput sequencing of the transcriptome showed that the expression of CTGF gene decreased after the administration of KD (C) The results of Real-Time PCR were consistent with the results of the sequencing. The expression of CTGF mRNA increased in the IR group, but decreased in the IR + KD group (D) The results of western blotting were consistent with the results of sequencing. The expression of CTGF protein increased in the IR group, but decreased in the IR + KD group (E) In the transcriptome KEGG gene pathway enrichment map, the TGF-β pathway was closely related to CTGF and RILF (F) The results of tissue TGF-β1 immunohistochemistry indicated that in the IR + KD group the expression of TGF-β1 in the liver tissue decreased compared with the IR group. For all results in this figure, original magnification, ×40 and ×100. Mean ± SEM. * p < 0.05, ** p < 0.01.
Index in PubMed under a CC BY license. PMID: 35126163

KD ameliorates the RILF by inhibiting TGF-β1/Smad/CTGF pathway (A) Exogenous TGF-β1 led to the increased expression of CTGF protein (B) Exogenous TGF-β1 induced an increase in the expression of collagen and a -SMA proteins (C) The TGF-β1 activity in the conditioned media significantly increased after 6Gy irradiation compared with the control group, while the TGF-β1 activity in the conditioned media in the IR + KD group decreased compared with the IR group (D-G) The expressions of TGF-β1 and downstream Smad2/3 as well as phosphorylated Smad2/3 reduced in the IR + KD group compared with the IR group. Mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
Index in PubMed under a CC BY license. PMID: 35126163

Top panel: representative slides showing immunohistochemical staining of connective tissue growth factor (CTGF) (stained in brown as shown by arrow) in the myocardium. Slides A , B , C , D represent control, diabetic, diabetic treated with low dose (2 μg · kg −1 .d −1 ) of exenatide and diabetic treated with high dose (10 μg · kg −1 .d −1 ) of exenatide, respectively. Magnifications × 400. Bottom: bar graph shows quantitative analysis of myocardial CTGF expression in control, diabetic and diabetic treated with low (2 μg · kg −1 .d −1 ) or high (10 μg · kg −1 .d −1 ) dose of exenatide. The CTGF expression was quantified using the average value of gray scale which had an inverse proportion to the positive stained intensity. Control (C, n = 7), diabetic (D, n = 10), diabetic treated with low dose (2 μg · kg −1 .d −1 ) of exenatide (DTL, n = 10), diabetic treated with high dose (10 μg · kg −1 .d −1 ) of exenatide (DTH, n = 9). Data are expressed as mean ± S.E.M. *P < 0.05 different from control, # P < 0.05 different from diabetic, $ P < 0.05 different from diabetic treated with low dose (2 μg · kg −1 .d −1 ) of exenatide.
Index in PubMed under a CC BY license. PMID: 24576329